Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

17.54 -5.48 (-23.83%)
Streaming Delayed Price Updated: 11:20 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗
According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy. 
Via Stocktwits
Topics Lawsuit
News headline image
Why Eli Lilly Stock Just Popped ↗
Novo Nordisk just did Eli Lilly stock a huge favor. 
Via The Motley Fool
Topics Lawsuit
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn
The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of... 
Via MarketMinute
Topics Earnings Intellectual Property
FDA "Swift Action" Warning Sends Hims & Hers into a Tailspin ↗
Via Chartmill
Dow Futures Push Higher After Breaking 50,000: Why OPGN, ACHR, LI, HIMS, CING Are Trending Today ↗
Via Stocktwits
Topics Stocks
News headline image
The GLP-1 Reckoning: Why Hims & Hers (HIMS) Pivoted and Shed 20% of Its Value
On February 9, 2026, the telehealth landscape faces a reckoning. Hims & Hers Health (NYSE: HIMS), a company that once seemed invincible during the weight-loss drug gold rush of 2025, is currently... 
Via Finterra
Topics Earnings Economy Intellectual Property
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks ↗
Novo stated that it has filed the lawsuit to protect its intellectual property and the American public. 
Via Stocktwits
Topics Intellectual Property Lawsuit
HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch ↗
Via Stocktwits
Novo Nordisk Threatens Legal Action Against Hims & Hers Over Compounded Wegovy Pill ↗
Via Stocktwits
HIMS Stock Garners Retail Buzz After Launching New Multi-Cancer Detection Test ↗
Via Stocktwits
Dow 50,000: A Milestone for the History Books Amidst an AI Spending War ↗
Via Chartmill
Topics Artificial Intelligence Stocks
News headline image
HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗
Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight. 
Via Stocktwits
Topics Intellectual Property Law Enforcement
News headline image
A Billion-Dollar Kickoff: Super Bowl LX Prediction Markets Hit Record $1B in Trading Volume
As the Seattle Seahawks and New England Patriots prepare to take the field for Super Bowl LX at Levi’s Stadium, the real action is happening on digital ledger boards and order books. In a historic... 
Via PredictStreet
Topics Derivatives
News headline image
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗
Via MarketBeat
News headline image
HIMS Stock Slumps After-Hours On Regulatory Scrutiny On Heels Of Compounded Wegovy Pill Launch ↗
The U.S. Food and Drugs Administration Commissioner Martin A Makary announced the agency’s intent to restrict the ingredients used by Hims as alternatives to FDA-approved drugs. 
Via Stocktwits
News headline image
The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market
The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Why Shares of Novo Nordisk Stock Collapsed This Week ↗
The drugmaker is facing pricing pressures on its weight loss medications. 
Via The Motley Fool
News headline image
Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗
The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs. 
Via Stocktwits
Topics Fraud Law Enforcement
News headline image
Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗
There's another fight brewing around GLP-1 drugs -- this time on the delivery side. 
Via The Motley Fool
News headline image
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
Via MarketMinute
Topics Earnings Economy
News headline image
Hims & Hers Takes On Novo Nordisk: What We Know Right Now ↗
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story. 
Via The Motley Fool
News headline image
Why Eli Lilly Stock Just Dropped ↗
Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there. 
Via The Motley Fool
News headline image
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗
The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month. 
Via Stocktwits
Topics Intellectual Property
News headline image
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering ↗
Hims & Hers is moving beyond prescriptions to preventative testing. 
Via The Motley Fool
News headline image
1 Volatile Stock for Long-Term Investors and 2 We Brush Off
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
News headline image
Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q3 Earnings?
Shareholders of Hims & Hers Health would probably like to forget the past six months even happened. The stock dropped 57.1% and now trades at $27.15. This may have investors wondering how to approach... 
Via StockStory
News headline image
1 Healthcare Stock to Research Further and 2 Facing Headwinds
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare... 
Via StockStory
Topics Stocks
News headline image
Will Netflix Go All-Cash for WBD? ↗
Netflix may be forced to offer all cash for WBD if the cable assets being spun off don't have the value Netflix thought they did. But is that something Netflix will do, and what are the risks? 
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.